HeartBeam was included in a report published by Modern Healthcare that highlighted companies that achieved meaningful regulatory milestones or demonstrated forward momentum.…
One of the key advantages of photodynamic therapy is its selectivity. Soligenix is advancing HyBryte(TM), or SGX301, designed for the…
While people have been quick to blame health insurers for the skyrocketing cost of health care in the U.S., the…
LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system This system provides several advantages over…
A planned preclinical study testing a light-activated therapy that helps to kill residual brain cancer cells after a patient has undergone surgery…
Researchers have developed a technological platform that leverages yeast cells to test and understand new cancer treatments under development. The use of…
The company has issued zero common shares since October 2023, marking a decisive break from typical OTC dilution patterns. A…
LIXTE’s lead compound, LB-100, targets PP2A, a central regulator of cancer cell survival and treatment resistance Clinical programs are designed…
According to recent data, health expenditures in the U.S. reached $5.3 trillion in 2024. That figure equates to 18% of GDP, and…
Although CTCL may progress slowly in its early stages, it remains a chronic and ultimately progressive disease for many patients.…